Viewing StudyNCT00124748



Ignite Creation Date: 2024-05-05 @ 11:45 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00124748
Status: TERMINATED
Last Update Posted: 2012-02-03
First Post: 2005-07-27

Brief Title: Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS Tyrosine Kinase Inhibitor Optimization and Selectivity
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Leukemia Myeloid Chronic Phase
Keywords:
Name View
CML View
Philadelphia positive View
Bcr-abl View
imatinib mesylate View
Chronic myeloid leukemia CML in chronic phase View